[Multi-center trial on the early effects of silodosin on lower urinary tract symptoms associated with benign prostatic hyperplasia].
Silodosin (URIEF), a new so-called 3rd generation alpha-1 blocker, is widely expected to be effective and useful for lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH), due to its high specificity to alpha-1A receptor. We evaluated the efficacy of Silodosin, on 187 males 50 years old or over with the diagnosis of BPH. Silodosin significantly improved the International Prostate Symptom Score (IPSS) and quality of life (QOL) score from the day after administration was started. Among 166 patients whose data were available for the analysis of efficacy of Silodosin, 77.5% showed apparent subjective improvement. Eighty three patients, who had been taking another alpha-1 blocker but without satisfactory effects, showed almost the same improvements in IPSS and QOL score after switching to Silodosin as the remaining 83 patients who had no preceding treatment with an alpha-1 blocker. The improvements were not only in voiding symptoms but also in storage symptoms. The patients, who had serious storage symptoms, responded rather well to Silodosin and showed significant improvement. Taken together, Silodosin showed a quick effect for improving subjective symptoms and QOL, and was found to be useful for the management of LUTS with BPH.
Ogawa
Takehiko
T
The Department of Urology, Yokohama City Univercity Graduate School of Medicine.
Uemura
Hiroji
H
Sano
Futoshi
F
Hoshino
Kouji
K
Kita
Kaoru
K
Hayashi
Narihiko
N
Kagota
Masayo
M
Murakami
Takayuki
T
Makiyama
Kazuhide
K
Miyoshii
Yasuhide
Y
Nakaigawa
Noboru
N
Yao
Masahiro
M
Shimura
Hidetoshi
H
Furuhata
Akihiko
A
Fujikawa
Naoya
N
Shioi
Koichi
K
Ueki
Teiichiro
T
Hara
Yoshinori
Y
Saitou
Kiyoshi
K
Kawakami
Satoshi
S
Satomi
Yoshiaki
Y
Hattori
Yusuke
Y
Teranishi
Junichi
J
Kondo
Keiichi
K
Kishida
Takeshi
T
Saito
Kazuo
K
Noguchi
Kazumi
K
Fuji
Hiroshi
H
Yamaguchi
Toyoaki
T
Kinoshita
Yuzo
Y
Nomura
Sakae
S
Yoshida
Minoru
M
Sakai
Naoki
N
Terao
Hideyuki
H
Matsumoto
Tatsuya
T
Umemoto
Susumu
S
Ogo
Yoshiharu
Y
Kobayashi
Kazuki
K
Noguchi
Sumio
S
Asakura
Tomoyuki
T
Kohdaira
Teruo
T
Iguchi
Kozue
K
Izumi
Koji
K
Hirano
Masami
M
Kanno
Hitomi
H
Takahashi
Toshihiro
T
Nukui
Fumihiko
F
Mokuo
Yasuhiro
Y
Muraoka
Kentaro
K
Osada
Yutaka
Y
Funahashi
Makoto
M
Kitami
Kazuo
K
Sugiura
Shimpei
S
Ohta
Junichi
J
Miura
Takeshi
T
Ishibashi
Yoshio
Y
Masuda
Mitsunobu
M
Komiya
Atsushi
A
Suwa
Yutaka
Y
Hashiba
Takafumi
T
Mitaka
Kunihisa
K
Kobayashi
Masataka
M
Ohsaka
Kimito
K
Futoshi
Takano
T
Tsuchiya
Tetsuzo
T
Iwasaki
Akira
A
Yamashita
Yuzo
Y
Matsuzaki
Junichi
J
Kubota
Yoshinobu
Y
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000368:Aged; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011788:Quality of Life
D000317:Adrenergic alpha-Antagonists; D007211:Indoles; C095285:silodosin